A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB068, a Bruton's Tyrosine Kinase Inhibitor, in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2017
At a glance
- Drugs BIIB 068 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Biogen
- 30 Jan 2017 Status changed from recruiting to completed.
- 01 Dec 2016 Planned number of patients changed from 52 to 50.
- 30 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.